183 related articles for article (PubMed ID: 17226962)
1. Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR.
Pan X; Wu G; Yang W; Barth RF; Tjarks W; Lee RJ
Bioconjug Chem; 2007; 18(1):101-8. PubMed ID: 17226962
[TBL] [Abstract][Full Text] [Related]
2. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
[TBL] [Abstract][Full Text] [Related]
3. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy.
Wu G; Barth RF; Yang W; Chatterjee M; Tjarks W; Ciesielski MJ; Fenstermaker RA
Bioconjug Chem; 2004; 15(1):185-94. PubMed ID: 14733599
[TBL] [Abstract][Full Text] [Related]
4. Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells.
Deng L; Zhang Y; Ma L; Jing X; Ke X; Lian J; Zhao Q; Yan B; Zhang J; Yao J; Chen J
Int J Nanomedicine; 2013; 8():3271-83. PubMed ID: 24023515
[TBL] [Abstract][Full Text] [Related]
5. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab-conjugated boron-containing liposomes for tumor-cell targeting; development and cellular studies.
Wei Q; Kullberg EB; Gedda L
Int J Oncol; 2003 Oct; 23(4):1159-65. PubMed ID: 12963999
[TBL] [Abstract][Full Text] [Related]
7. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab.
Wu G; Yang W; Barth RF; Kawabata S; Swindall M; Bandyopadhyaya AK; Tjarks W; Khorsandi B; Blue TE; Ferketich AK; Yang M; Christoforidis GA; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA
Clin Cancer Res; 2007 Feb; 13(4):1260-8. PubMed ID: 17317838
[TBL] [Abstract][Full Text] [Related]
8. Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma.
Lehtinen J; Raki M; Bergström KA; Uutela P; Lehtinen K; Hiltunen A; Pikkarainen J; Liang H; Pitkänen S; Määttä AM; Ketola RA; Yliperttula M; Wirth T; Urtti A
PLoS One; 2012; 7(7):e41410. PubMed ID: 22844475
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells.
Petrilli R; Eloy JO; Lopez RF; Lee RJ
Anticancer Agents Med Chem; 2017; 17(2):301-308. PubMed ID: 27225449
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
11. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
[TBL] [Abstract][Full Text] [Related]
12. Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity.
Pan X; Lee RJ
Int J Pharm; 2007 May; 336(2):276-83. PubMed ID: 17212981
[TBL] [Abstract][Full Text] [Related]
13. Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT).
Thirumamagal BT; Zhao XB; Bandyopadhyaya AK; Naranyanasamy S; Johnsamuel J; Tiwari R; Golightly DW; Patel V; Jehning BT; Backer MV; Barth RF; Lee RJ; Backer JM; Tjarks W
Bioconjug Chem; 2006; 17(5):1141-50. PubMed ID: 16984121
[TBL] [Abstract][Full Text] [Related]
14. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.
Yang W; Barth RF; Wu G; Tjarks W; Binns P; Riley K
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S328-31. PubMed ID: 19467880
[TBL] [Abstract][Full Text] [Related]
15. Skin cancer treatment effectiveness is improved by iontophoresis of EGFR-targeted liposomes containing 5-FU compared with subcutaneous injection.
Petrilli R; Eloy JO; Saggioro FP; Chesca DL; de Souza MC; Dias MVS; daSilva LLP; Lee RJ; Lopez RFV
J Control Release; 2018 Aug; 283():151-162. PubMed ID: 29864476
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.
Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y
Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787
[TBL] [Abstract][Full Text] [Related]
17. Dodecaborate lipid liposomes as new vehicles for boron delivery system of neutron capture therapy.
Ueno M; Ban HS; Nakai K; Inomata R; Kaneda Y; Matsumura A; Nakamura H
Bioorg Med Chem; 2010 May; 18(9):3059-65. PubMed ID: 20371186
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
19. Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent.
Barth RF; Wu G; Yang W; Binns PJ; Riley KJ; Patel H; Coderre JA; Tjarks W; Bandyopadhyaya AK; Thirumamagal BT; Ciesielski MJ; Fenstermaker RA
Appl Radiat Isot; 2004 Nov; 61(5):899-903. PubMed ID: 15308165
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.
Wu G; Barth RF; Yang W; Kawabata S; Zhang L; Green-Church K
Mol Cancer Ther; 2006 Jan; 5(1):52-9. PubMed ID: 16432162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
